

The Pharmacological Basis of Therapeutics

FIFTH EDITION

Editors:

Louis S. Goodman

and

Alfred Gilman

Associate Editors:

Alfred G. Gilman

and

George B. Koelle

Best Available Copy

respiratory depression. They are also used in the diagnosis of physical dependence on narcotic drugs and as therapeutic agents in the treatment of compulsive narcotics users, as discussed in Chapter 16. Partial agonists are also used as analgesics (see Table 15-3).

Treatment of Narcotic Overdosage. The dramatic effects of opioid antagonists in reversing narcotic-induced respiratory depression in the adult have already been discussed. Narcotic antagonists have also been effectively employed to decrease neonatal respiratory depression secondary to the administration of narcotics to the mother. When employed for this purpose, the antagonist may be given either to the mother shortly before delivery (preferable) or to the infant by way of the umbilical vein following delivery. The usual dose of naloxone is 0.4 or 0.8 mg for the mother; a therapeutic dose has not been established for the newborn, but 5 µg/kg has been given without adverse effects. Narcotic antagonists cannot be expected to decrease apnea of the newborn caused by trauma of delivery or other factors; they are not effective antagonists against drugs other than opioid narcotics. There is an overwhelming body of evidence showing that all known narcotics, even in reasonable therapeutic doses (e.g., 10 mg of morphine, 100 mg of meperidine), produce a significant increase in the incidence of neonatal depression compared to deliveries in which no general anesthetic or narcotic is used. This increased depression is not great; however, even if the use of narcotic antagonists results in only a slight decrease in the incidence of such respiratory depression, their routine use would still appear justified whenever narcotics are administered during labor (see review by Eddy *et al.*, 1957). Antagonists with agonistic actions, such as nalorphine or levallorphan, should be used only when naloxone is unavailable.

Analgesia. Pure opioid antagonists are of no value as analgesics and, because of their unpleasant side effects, agonists of the nalorphine type have not been widely used. Partial agonists of the morphine type, such as propiram, may be used in the near future. Pentazocine is discussed separately, below.


It should be emphasized that the risk of dependence is not a major limiting factor in the use of opioid analgesics for the relief of pain in acute situations. Thus, the major advantage of analgesics with low abuse liability is limited to conditions where analgesics must be given chronically or to persons whose personalities suggest a predisposition to develop psychological dependence.

PENTAZOCINE

Pentazocine is one of the many compounds synthesized as part of a deliberate effort to develop an effective analgesic with little or no abuse potential. A benzomorphan derivative, pentazocine has both agonistic actions and weak opioid antagonistic activity. It is too weak an antagonist to be classed with nalorphine, and it is also inappropriate to group it with morphine and the other opioids. The pharma-

cology of pentazocine has been reviewed by Brogden and associates (1973).

Chemistry. Pentazocine, a white powder soluble in acidic aqueous solutions, has the following structural formula:



The analgesic and respiratory depressant activity of the racemate is due mainly to the *l* isomer.

Pharmacological Actions. Like most opioids, pentazocine exerts its major effects on the CNS and smooth muscle. The pattern of CNS effects is generally similar to that of the opioids, including analgesia, sedation, and respiratory depression. A dose of approximately 20 mg of the racemate or 13 mg of the *l* isomer produces the same degree of respiratory depression as does a 10-mg dose of morphine (see Bellville and Forrest, 1968). Increasing the dose of pentazocine beyond 30 mg does not ordinarily produce proportionate increases in respiratory depression (Engineer and Jennett, 1972). However, at doses of 60 to 90 mg, nalorphine-like dysphoric and psychotomimetic effects may occur that can be antagonized by naloxone but not by nalorphine.

The effects of pentazocine on the gastrointestinal tract are qualitatively similar to those of the opioids. Relatively small intramuscular doses (15 mg) significantly decrease gastric emptying time; higher doses (30 to 45 mg) increase the transit time through the intestinal tract (Danhof, 1967), but produce less elevation of biliary pressure than equianalgesic doses of morphine (Economou and Ward-McQuaid, 1971).

The cardiovascular responses to pentazocine differ somewhat from those seen with the opioids, in that high doses cause an increase in blood pressure and heart rate. In normal subjects, pentazocine causes a decrease in effective renal plasma flow but no decrease in glomerular filtration rate (Sigman and Elwood, 1967). In patients with coronary artery disease, pentazocine (intravenously) elevates mean aortic pressure, left ventricular end-diastolic pressure, and mean pulmonary artery pressure, and causes an increase in cardiac work (Alderman *et al.*, 1972). Pentazocine produces a rise in plasma epinephrine and norepinephrine, and this may account for its effects on blood pressure (Tammisto *et al.*, 1971).


The effects of pentazocine on uterine contractility do not appear to differ from those of meperidine.

Pentazocine also has weak narcotic antagonistic activity (approximately one fiftieth as potent as nalorphine). It does not antagonize the respiratory depression produced by morphine; however, when given to patients who have been receiving opioids

Best Available Copy

ed by Brogden

white powder soluble
the following struc-



pressant activity of
the isomer.

like most opioids,
acts on the CNS and
CNS effects is gen-
erally, including anal-
gesia and depression. A dose
of 10 mg or 13 mg
produces a degree of respira-
tory depression of morphine
dose. Increasing the dose
does not ordinarily
increase respiratory de-
pression (1972). However, at
higher doses, dysphoric and
anxiety can be an-
tagonized by nalorphine.

the gastrointestinal
effects of the opioids.
Doses (15 mg) signifi-
cantly higher doses
pass through the
stomach but produce less
analgesic effect (Jasinski
and McQuaid, 1971).
Pentazocine differs
from the opioids, in that
it causes a drop in blood pressure and
anxiety. Pentazocine causes a
drop in blood pressure but no de-
pression (Sigman and
Morrison, 1971). It elevates mean
arterial and diastolic pres-
sure, and (Alderman *et al.*,
1971). The increase in plasma epi-
nephrine may account
for this (Tammisto *et al.*,

terine contractility
of meperidine.
Pentazocine is an-
tagonistic as
potent as nalor-
phine in respira-
tory de-
pression; however, when
receiving opioids

on a regular basis, it may precipitate opioid with-
drawal symptoms (Beaver *et al.*, 1966). In patients
tolerant to opioids, pentazocine reduces the anal-
gesia produced by morphine, even when clear-cut
withdrawal symptoms are not produced.

Absorption, Fate, and Excretion. Pentazocine is
well absorbed from the gastrointestinal tract and
from subcutaneous and intramuscular sites. Plasma
levels coincide closely with the onset, duration, and
intensity of analgesia; peak concentrations occur 15
minutes to 1 hour after intramuscular administration
and 1 to 3 hours after oral administration. Plasma
half-life after intramuscular administration is about
2 hours; plasma levels are still elevated at 5 hours
after oral administration (Berkowitz *et al.*, 1969).

Although some free pentazocine is excreted in the
urine, the action of the drug is terminated largely
by biotransformation in the liver; the metabolites,
products of the oxidation of the terminal methyl
groups and glucuronide conjugates, are excreted by
the kidney, and approximately 60% of the total dose
is eliminated within the first 24 hours. There is con-
siderable variability between individuals in terms of
rate of pentazocine metabolism, and this may ac-
count for the variability of analgesic response (see
Brogden *et al.*, 1973). Pentazocine passes the placen-
tal barrier but to a lesser extent than does meperi-
dine (Beckett and Taylor, 1967).

**Preparations, Routes of Administration, and Dos-
age.** *Pentazocine Lactate Injection*, N.F. (FORTAL,
TALWIN), is available in 1-, 1.5-, and 2-ml ampuls
and 10-ml multiple-dose vials, each milliliter con-
taining an amount equivalent to 30 mg of the base.
Pentazocine Hydrochloride Tablets, N.F., for oral use
contain 50 mg of the base. Pentazocine is somewhat
irritating when administered subcutaneously or in-
tramuscularly. In terms of analgesic effect, a 30- to
50-mg dose given parenterally is approximately
equivalent to 10 mg of morphine. A dose of about
50 mg of oral pentazocine results in analgesia equiv-
alent to that produced by 60 mg of codeine. In terms
of peak effect, pentazocine is approximately one
fourth as potent orally as parenterally; in terms of
total analgesic effect, one third as potent. (See Beaver
et al., 1966, 1968; Kantor *et al.*, 1966; Morrison
et al., 1971.)

Side Effects, Toxicity, and Precautions. Side
effects from pentazocine differ somewhat from those
of opioids. The most commonly reported effect is
sedation, followed by sweating, and dizziness or
light-headedness; nausea also occurs, but vomiting
is less common than with morphine. Nalorphine-like
psychotomimetic effects such as anxiety, nightmares,
weird thoughts, and hallucinations have been re-
ported. These are not common with doses in the
therapeutic range (see Paddock *et al.*, 1969) but are
seen with increasing frequency with doses above
60 mg. The clinical picture of overdosage has not
been well defined. High doses produce marked res-
piratory depression associated with increased blood
pressure and tachycardia. The respiratory depression
is antagonized by naloxone but not by nalorphine.

Patients who have been receiving opioids on a regu-
lar basis may experience withdrawal symptoms when
given pentazocine. After an opioid-free interval of
1 to 2 days, it is usually possible to administer penta-
zocine without producing such withdrawal effects.

**Tolerance, Physical Dependence, and Abuse Po-
tential.** With frequent and repeated use, some tol-
erance develops to the analgesic and subjective
effects of pentazocine; however, it is not clear if the
rate of development of this tolerance is comparable
to that seen with narcotic analgesics or is the same
for all effects of the drug. When given intravenously
or subcutaneously to postaddicts, pentazocine
(40 mg) produces essentially morphine-like effects;
when the dose is increased to 60 mg, the effects begin
to resemble the nervousness and loss of energy pro-
duced by nalorphine. In contrast to morphine and
other opioids, pentazocine does not prevent or ame-
liorate the morphine withdrawal syndrome when
substituted in subjects physically dependent on mor-
phine. Instead, when high doses of pentazocine are
given to such subjects, its antagonistic actions, al-
though weak, precipitate withdrawal symptoms.

Postaddicts given high doses spaced closely
enough to produce continuous action on the nervous
system (e.g., 60 to 90 mg every 4 hours) consistently
develop physical dependence that can be demon-
strated by abrupt withdrawal or precipitated by
naloxone but not by nalorphine. The withdrawal
syndrome after chronic doses of more than 500 mg
per day is similar in some respects to that seen after
withdrawal of nalorphine, but it also has some of
the characteristics of opioid withdrawal and, al-
though milder, may be associated with drug-seeking
behavior; that is, subjects request additional medi-
cine to alleviate the withdrawal syndrome (Jasinski
et al., 1970).

In the original evaluation of the abuse potential
of pentazocine, most postaddicts who were offered
the opportunity to continue taking the drug elected
not to do so, and few subjects in the chronic admin-
istration studies reached sufficiently high dosage to
exhibit withdrawal phenomena upon abrupt discon-
tinuation (Fraser and Rosenberg, 1964). Pentazocine
was not considered to have a significant abuse po-
tential, and it was released for general use subject
to neither narcotic laws nor dangerous drug laws.
Many physicians believed that the drug had no
abuse potential at all and, therefore, were less than
cautious in prescribing it, in permitting unlimited
refilling of prescriptions, and in allowing its self-
administration by ambulatory patients. Subse-
quently, cases of compulsive self-administration pri-
marily of parenteral pentazocine were reported.
Many, but not all, of these individuals previously
had been dependent on opioids; most would have
preferred opioids if the latter had been legal and
equally available. The withdrawal symptoms seen in
many of these cases included abdominal cramps,
anxiety, chills, elevated temperature, vomiting,
sweating, lacrimation, and drug-seeking behavior.

As the abuse potential of parenteral pentazocine
became more widely appreciated, more supervision
was exercised by physicians and pharmacists. The
availability of the oral preparation reduced the

Best Available Copy